# Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients

> **NCT02442206** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 62 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease, COPD

## Interventions

- **DRUG:** QVA149
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02442206
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-18
- **Primary completion:** 2017-04-20
- **Final completion:** 2017-05-15
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2019-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02442206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02442206, "Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02442206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*